Publications

Journal Article
Review
Ppublish 53 citations
Electronic publication date
October 25, 2012

View on Pubmed.gov 22730341 | View on doi.org 10.1002/emmm.20...

Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications.

Search for publications in this journal EMBO Mol Med - 4(7):545-56

Abstract

Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes. What was once regarded as a mere signal for protein degradation has turned out to be a major regulator of molecular signalling networks. Deregulation of ubiquitin signalling is closely associated with various human pathologies. Here, we summarize the current knowledge of ubiquitin signalling in immune deficiencies and cancer as well as the available therapeutic strategies targeting the ubiquitin system in combating these pathogenic conditions.

References

Nature. 1992 May 14;357(6374):161-4

Nat Rev Mol Cell Biol. 2011 May;12(5):295-307

EMBO Rep. 2008 Sep;9(9):930-6

Genes Cancer. 2010 Dec;1(12):1170-7

Cited by 53 citations (total)

Journal Article Review Research Support, Non-U.S. Gov't

CUL4-Based Ubiquitin Ligases in Chromatin Regulation: An Evolutionary Perspective.

Electronic publication date January 24, 2025

Search for publications in this journal Cells

Makiko Nakagawa [...] Tadashi Nakagawa et al.

Ubiquitylation is a post-translational modification that modulates protein function and stability. It is orchestrated by the concerted action of three...

Journal Article Research Support, Non-U.S. Gov't

The repertoires of ubiquitinating and deubiquitinating enzymes in eukaryotic genomes.

Electronic publication date November 1, 2013

Search for publications in this journal Mol Biol Evol

Andrew Paul Hutchins [...] Diego Miranda-Saavedra et al.

Reversible protein ubiquitination regulates virtually all known cellular activities. Here, we present a quantitatively evaluated and broadly applicable method to...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

Copyright © 2012 EMBO Molecular Medicine.